Skip to main content

Table 1 Comparison of baseline characteristics between the registry cohorts versus relevant studies providing evidence on secondary stroke prevention in atrial fibrillation

From: Baseline characteristics in stroke patients with atrial fibrillation: clinical trials versus clinical practice

  Hessian stroke registry (2004–2010) n = 15,886 Insurance (total Cohort) n = 1,828 Insurance (subgroup of patients with prescription for AK) n = 827 EAFT (1993) n = 669 SIFA (1997) n = 916 Active-W (2006) n = 6,706 BAFTA (2007) n = 973 AVERROES (2011) n = 5,599 RE-LY (2010) n = 18,113 ARISTOTLE (2011) n = 18,201 ROCKET AF (2012) n = 14,264
Age (years) mean, ±SD 77.7 (±9) 77.6 (±8) 75.1(± 8) 71 (±7) 72 (± 8) 70.2 81.5 (±8) 70 ± 9 70 (±9)a 70.1 (±9.7)a 71 (median)a
(IQR 64–77)
Sex
 Male 7,312 (46%) 764 (41.8%) 398 (48.1%) 395 (59%) 430 (47%) 4,430 (66%) 531 (55%) 3,277 (59%) 2,279 (63%)a,† 2,152 (63%)a,† 4,538(61%)a,†
 Female 8,574 (53%) 1,064 (58%) 429 (51.9%) 274 (41%) 486 (53%) 2,276 (34%) 442 (45%) 2,322 (41%) 1,344 (37%)a,† 1,284 (37%)a,† 2,930(39%)a,†
Risk factors
 Hypertension 12,679 (80%) 1,444 (79%) 660 (79.8%) 294 (44%) 506 (55%) 5,522 (82%) 528 (54%) 4,837 (86%) 2,783 (77%)a,† 2,858 (83%)a,† 6,343 (85%)a,†
 Diabetes mellitus 4,371 (27%) 530 (29%) 240 (29%) 87 (13%) 144 (16%) 1,429 (21%) 129 (13%) 1,096 (20%) 816 (22%)a,† 902 (26%)a 5,695 (24%)a,†
Proportion of Strokes or TIAs within the study population 100% 100% 100% 100% 100% 15% (n = 1,006) 13% (n = 124) 14% (n = 764) 20% (n = 3,623) 19% (n = 3,436) 52% (n = 7,468)
Comparison of agents Warfarin vs. placebo and aspirin vs. placebo Indobufenb vs. warfarin Aspirin + clopidogrel vs. warfarin Warfarin vs. aspirin Apixaban vs. aspirin Dabigatran vs. warfarin Apixaban vs. warfarin Rivoroxaban vs. warfarin
  1. aData refers to the subgroup of patients with a previous stroke or TIA.
  2. bIndobufen is a reversible inhibitor of platelet cyclooxygenase activity.
  3. p value <0.001 calculated with a Chi square test (comparison between the entire cohort determined in the hessian stroke registry (n = 15,886) and the EAFT cohort, the SIFA cohort and the stroke subgroups in RE-LY, ARISTOTLE and ROCKET AF).